The Female Health Company to Present at Sidoti's Eighth Semi-Annual New York Micro-Cap Conference
Jan 6, 2014
CHICAGO, Jan. 6, 2014 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), which manufactures and markets the FC2 Female Condom®, today announced that it will be presenting at Sidoti & Company's Eighth Semi-Annul Micro-Cap Conference on Monday, January 13, 2014. The conference will be held at the Grand Hyatt New York Hotel in midtown Manhattan.
The presentation by O.B. Parrish, Chief Executive Officer, and Michele Greco, Chief Financial Officer, is scheduled for 1:30 p.m. Eastern Standard Time. Management will be available during the day for one-on-one meetings. Investors interested in arranging one-on-one meetings should contact their Sidoti representative.
About Sidoti & Company, LLC
Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for independent small-cap equity research, while rapidly becoming a driving force in micro-cap research, launching coverage of more than 400 equities of $250 million market cap or less since mid-2010. Its analysts mine dozens of industries to provide unbiased, institutional-quality research focusing on the investment merits of profitable companies at a sub-$3 billion market cap, and it continues to expand its coverage of micro-cap equities.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 143 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by the FDA that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health Company
For further information: William R. Gargiulo, Jr., 231.526.1244, or Michele Greco, CFO, 312.595.9123